2019
853P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Stenzl A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore N, Rosbrook B, Baron B, Haas G, Morlock R, Ramaswamy K, Armstrong A. 853P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups. Annals Of Oncology 2019, 30: v332-v333. DOI: 10.1093/annonc/mdz248.010.Peer-Reviewed Original ResearchRadiographic progression-free survivalAndrogen deprivation therapyMetastatic hormone-sensitive prostate cancerCastration-resistant prostate cancerSymptomatic skeletal eventsProgression-free survivalDisease volumeOverall survivalRisk groupsAdverse eventsQuality of lifeAstellas PharmaBristol-Myers SquibbDeprivation therapyVisceral metastasesSkeletal eventsRadiographic responseTrial criteriaBone lesionsProstate cancerHigher QoLHormone-sensitive prostate cancerProstate-specific antigen progressionAstellas Pharma Inc.Genentech/Roche
2018
PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.
Morris M, Vogelzang N, Sartor A, Armour A, Messmann R, Groaning M, Robarts A, Tolcher A, Gordon M, Babiker H, Kuo P, Kearney M, Jendrisak A, Wang Y, Landers M, Petrylak D. PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs. Journal Of Clinical Oncology 2018, 36: 272-272. DOI: 10.1200/jco.2018.36.6_suppl.272.Peer-Reviewed Original ResearchMetastatic castrate-resistant prostate cancerProstate-specific membrane antigenSPECT/CT scansHomologous recombination deficiency scoresPSMA expressionProstate cancerCT scanPre-treatment blood samplesDeficiency scoresCastrate-resistant prostate cancerBiomarker analysisSoft tissue lesionsSPECT/CTTherapeutic predictive valueDetectable CTCsNaïve patientsBone scanBad respondersClinical outcomesBaseline CTBone lesionsPositive lesionsBlood samplesTissue lesionsTherapeutic target